2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2229 Immunogenicity and safety of the recombinant adjuvanted respiratory syncytial virus vaccine in patients with chronic lymphocytic leukemia and multiple myeloma

Panagiotis Diamantopoulos, MD, PhD, Christos Stafylidis, MD, MSc2, Christina-Nefeli Kontandreopoulou, BSc3, Iraklis Patsialos, MD4, Konstantinos Sideris5, Thomas Thomopoulos, MD6, Anthi Bouchla7, Maria-Lamprini Kasti, MD8, Andreas Epameinondas Koumpis9, Eleftherios Athanasopoulos10, Eleftheria Hatzimichael, MD11, Vasiliki Lampropoulou12, Vasiliki Pappa, MD13, Marina Mantzourani14
1 National and Kapodistrian University of Athens, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece
4 National and Kapodistrian University of Athens, Athens, Greece
5 National and Kapodistrian University of Athens, Athens, Greece
6 Attikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece
7 Attikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece
8 University Hospital of Patras, University of Patras, Rion, Greece
9 Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
10 University of Patras, Patras, Greece
11 Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
12 University Hospital of Patras, University of Patras, Rion, Greece
13 Attikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece
14 National and Kapodistrian University of Athens, Athens, Greece

Bacterial and viral infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), while disease- and treatment-related immunosuppression also impairs vaccine-induced immune responses.

Respiratory syncytial virus (RSV) is an important cause of severe lower respiratory tract infection in patients with hematological malignancies, with 30-day mortality rates of up to 9%. The recombinant adjuvanted RSV vaccine (Arexvy®) has been approved for adults at increased risk of RSV disease. Although the vaccine has demonstrated efficacy and safety in immunocompetent older adults, data in immunocompromised patients, particularly those with CLL and MM, remain limited.

Aims and methods

We conducted a multicenter study to evaluate the immunogenicity and safety of Arexvy® in adult patients with CLL and MM. Written informed consent was obtained from all participants. The demographic, clinical, and treatment characteristics, and the pre- and post-vaccination laboratory results of the patients were recorded.

Patients were vaccinated with a single intramuscular dose of 0.5 mL of Arexvy® (combining 120 mcg of the recombinant form of the RSV fusion glycoprotein with AS01E, a liposome-based adjuvant system).

The primary endpoint of the study was to assess the immunogenicity of the vaccine by measuring the anti-RSV IgG antibodies at baseline and 28 days post-vaccination, using the commercially available EUROIMMUN assay panel-IgG (Medizinische Labordiagnostika AG, Lubeck, Germany), with a sensitivity and specificity of 100% and 96.2%, respectively, and a cut-off value of ≥22 RU/mL. Secondary endpoints included assessment of changes in seropositivity, correlation of antibody titers with baseline and treatment characteristics, and vaccine safety.

The study was approved by the Institutional Review Boards of the participating centers.

Results

The study included 170 patients (69 with CLL and 101 with MM) with a median age of 74.8 years.

The median interval between pre-vaccination sampling and vaccination was 3 days (range 0-17), while baseline IgG seropositivity was 67.8%, with a median antibody titer of 44.4 RU/mL (0-146.7). Out of 170 patients, 153 received vaccination (90.0%), and 149 (87.6%) had a post-vaccination sample. The median interval between vaccination and post-vaccination sampling was 29 days (18-45). Post-vaccination IgG seropositivity increased to 94.6% (p<0.001), with a corresponding statistically significant increase in the IgG titer to 81.8 RU/mL (8.7-158.3, p<0.001).

Neither baseline nor post-vaccination IgG titers were associated with age, sex, or baseline hematological parameters. Median baseline IgG titers differed significantly according to treatment status, with treatment-naïve and non-actively treated patients exhibiting higher titers than actively treated patients (67.3 vs 31.5 RU/mL, p<0.001). Baseline IgG titers were significantly higher in patients with CLL than in those with MM (61.2 vs 29.3 RU/mL, p=0.001), but post-vaccination titers were higher in MM than in CLL (88.7 vs 73.2 RU/mL, p=0.027). Similar differences were observed for IgG seropositivity. A >4-fold increase in antibody titers was observed in 36.7% of patients with MM compared with only 6.7% of those with CLL. In patients with MM (but not CLL), both pre- and post-vaccination IgG titers were significantly lower in actively treated patients (21.7 vs 82.1 RU/mL, p=0.005, and 87.4 vs  111.7 RU/mL, p=0.046, respectively). No association was observed between antibody titers or seropositivity and prior exposure to rituximab, venetoclax, or BTK inhibitors in patients with CLL, or daratumumab in patients with MM.

Only mild local adverse events were recorded during follow-up, with no serious vaccine-related adverse events.

Discussion

Two-thirds of patients with CLL and MM had detectable anti-RSV IgG antibodies before vaccination (67.8%), and this rate increased to 94.6% after vaccination. Although patients with CLL had higher baseline anti-RSV IgG titers, patients with MM mounted a greater humoral response following vaccination. Moreover, treatment-naïve patients in both groups had higher pre-vaccination antibody titers, while actively treated patients had the lowest baseline levels. Active treatment was associated with impaired post-vaccination antibody responses only in MM patients. These findings support RSV vaccination in patients with CLL or MM, including those receiving active treatment.
Vasiliki Pappa, MD: Roche - Honoraria; Gilead - Honoraria; Genesis Pharma - Honoraria; Astrazeneca - Honoraria; BMS - Honoraria; Servier - Honoraria; GSK - Honoraria; Swixx - Honoraria; Amgen - Honoraria; Novartis - Honoraria; Janssen - Honoraria; Sobi - Honoraria; AbbVie Pharmaceuticals S.A - Honoraria; Pfizer - Honoraria; Janssen - Research Funding; Celgene - Research Funding; AbbVie Pharmaceuticals S.A - Research Funding; GSK - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Genesis Pharma - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Swixx - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Astrazeneca - Consultancy (Includes expert testimony); AbbVie Pharmaceuticals S.A - Consultancy (Includes expert testimony)